Takeda Pharmaceutical Company Limited Stock
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Japan Exchange
09:30:00 13/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 5,963.00 JPY | +2.05% |
|
+4.27% | +23.33% |
| 10-08 | Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom | RE |
| 10-07 | Pharmaceutical Group Sues US Government Over Medicare Drug Pricing Rule | MT |
| Market Cap | 9,330B 58.77B 52.61B 49.05B 44.49B 83.91B 5,618B 84.43B 589B 231B 2,899B 221B 216B | P/E 2027 * |
46.3x | P/E 2028 * | 29.4x |
|---|---|---|---|---|---|
| Enterprise Value | 13,236B 83.38B 74.64B 69.58B 63.12B 119B 7,971B 120B 836B 327B 4,113B 313B 306B | EV / Sales 2027 * |
2.81x | EV / Sales 2028 * | 2.72x |
| Free-Float |
99.25% | Yield 2027 * |
3.5% | Yield 2028 * | 3.57% |
| Markets | Quality | ||
|---|---|---|---|
Japan Exchange
| 4502 | Delayed | |
OTC Markets
| TKPHF | Delayed | |
|
Tradegate
| TKD | Real-time | |
|
Boerse Muenchen
| TKD | Real-time | |
|
Deutsche Boerse AG
| TKD | Delayed | |
|
Börse Stuttgart
| TKD | Delayed | |
|
Wiener Boerse
| TKD | End-of-day quote |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +2.05% | ||
| 1 week | +4.27% | ||
| Current month | +3.17% | ||
| 1 month | +3.94% | ||
| 3 months | +12.13% | ||
| 6 months | +5.80% | ||
| Current year | +23.33% |
| 1 week | 5,708 |  | 5,990 |
| 1 month | 5,606 | | 6,030 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2025 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 01/04/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 61 | 01/06/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 01/01/2019 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 01/06/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/14/26 A | Sell | Executive/Senior Manager | -34,535 | 0.0022% | ||
| 9/2/26 A | Sell | Chief Technology Officer | -116,191 | 0.0073% | ||
| 8/19/26 A | Sell | Chief Technology Officer | -19,651 | 0.0012% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.05% | +4.27% | +41.04% | +31.17% | 58.77B | |
| +0.28% | +3.46% | +41.89% | +93.71% | 1,054B | |
| +0.88% | +4.27% | +38.28% | +68.70% | 636B | |
| +1.68% | +5.78% | +21.96% | +89.56% | 497B | |
| -0.10% | +4.24% | +69.15% | +40.41% | 359B | |
| +1.72% | +4.77% | +26.34% | +43.70% | 345B | |
| +1.43% | +4.03% | +16.65% | +39.28% | 273B | |
| +2.00% | +2.69% | -3.49% | +11.90% | 246B | |
| +0.65% | +3.62% | +43.93% | +46.50% | 226B | |
| -0.49% | +4.01% | +28.38% | +95.97% | 187B | |
| Average | +0.94% | +3.18% | +32.41% | +56.09% | 388.1B | |
| Weighted average by Cap. | +0.71% | +3.20% | +34.68% | +67.10% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,704B 29.63B 26.53B 24.73B 22.43B 42.3B 2,832B 42.57B 297B 116B 1,462B 111B 109B | 4,794B 30.2B 27.04B 25.2B 22.86B 43.12B 2,887B 43.39B 303B 119B 1,490B 113B 111B |
| Net income | 196B 1.24B 1.11B 1.03B 937M 1.77B 118B 1.78B 12.41B 4.86B 61.06B 4.65B 4.55B | 323B 2.03B 1.82B 1.7B 1.54B 2.9B 194B 2.92B 20.39B 7.98B 100B 7.64B 7.47B |
| Net Debt | 3,907B 24.61B 22.03B 20.54B 18.63B 35.13B 2,352B 35.35B 247B 96.61B 1,214B 92.44B 90.39B | 3,702B 23.32B 20.88B 19.46B 17.65B 33.3B 2,229B 33.5B 234B 91.56B 1,150B 87.61B 85.67B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/10/26 | ¥5,963.00 | +2.05% | 4,001,400 |
| 09/10/26 | ¥5,843.00 | +0.46% | 3,664,000 |
| 08/10/26 | ¥5,816.00 | +0.87% | 4,535,300 |
| 07/10/26 | ¥5,766.00 | +0.82% | 3,222,600 |
| 06/10/26 | ¥5,719.00 | +1.42% | 3,536,400 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
